Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases.
The behavior of tumor-associated trypsin inhibitor (TATI) as a marker for gynecological cancer was studied in a control population and in patients with different benign and malignant diseases. When a cut-off level of 21.4 micrograms/l was used the specificity was 100% in patients with benign diseases. The sensitivity in patients with malignant tumors was low for cervical and corpus cancer, 13% and 14%, respectively, whereas it was 33% in all the ovarian malignant tumors, reaching 60% in the mucinous type. There was a clear correlation between TATI level and stage.
Torre
G C
GC
Department of Gynecology and Obstetrics, S. Corona Hospital, Pietra Ligure, Italy.
Rembado
R
R
Barbetti
V
V
Vigliercio
G P
GP
Foglia
M
M
Calabrese
A
A
Corongiu
F
F
D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D005831:Genital Diseases, Female / Q000097:blood / Q000175:diagnosis*; D005833:Genital Neoplasms, Female / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D012907:Smoking / Q000097:blood; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000097:blood*
D014408:Biomarkers, Tumor; D014359:Trypsin Inhibitor, Kazal Pancreatic